title: An initial clinical study on the efficacy of cisplatin-releasing gelatin microspheres for metastatic liver tumors.
abstract: OBJECTIVE
  To evaluate the antitumor effect and side effects of cisplatin-releasing gelatin microspheres (Cis-GMSs) for metastatic liver tumors.
  
  
  METHODS
  Cis-GMSs that degraded over 14 days were employed. The subjects comprised a total of nine cases. Transcatheter hepatic artery embolization (TAE) using Cis-GMSs (Cis-GMSs-TAE) was performed 13 times in total. Six cases, each containing one to five tumors in a single segment to an entire lobe were treated by Cis-GMSs-TAE. In the remaining three cases with six or more metastatic liver tumors, the right and left lobes were treated by Cis-GMSs-TAE at a 2-week interval.
  
  
  RESULTS
  There were two complete response (CR), one partial response (PR) and six stable disease (SD) cases. The response rate was 33.3%. The average rate of reduction in tumor diameter was 32%. Disappearance of metastatic liver tumors was observed in only two of the nine cases. As for side effects and complications, post-embolization syndrome was observed in eight cases, but no severe complications such as cholangitis or liver abscess were observed.
  
  
  CONCLUSIONS
  Considering the mild side effects by Cis-GMSs-TAE, it is suggested that Cis-GMSs-TAE should be tried at least once as topical therapy for metastatic liver tumors when the response to systemic chemotherapy and other treatments is not satisfactory.
authors.affiliation: Department of Radiology, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga 520-2192, Japan. r34nitta@yahoo.co.jp
authors.forename: Norihisa
authors.initials: N
authors.lastname: Nitta
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ohta
authors.forename: Toyohiko
authors.initials: T
authors.lastname: Tanaka
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Takazakura
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Toyama
authors.forename: Akinaga
authors.initials: A
authors.lastname: Sonoda
authors.forename: Ayumi
authors.initials: A
authors.lastname: Seko
authors.forename: Akira
authors.initials: A
authors.lastname: Furukawa
authors.forename: Masashi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Murata
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kurumi
authors.forename: Toru
authors.initials: T
authors.lastname: Tani
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sakamoto
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage* / Q000737:chemistry; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry; D005260:Female; D005780:Gelatin / Q000737:chemistry; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D005780:Gelatin; D002945:Cisplatin